Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MyClad: Oral Cladribine in Generalized Myasthenia Gravis
NCT06463587Phase 3Recruiting
- Sponsor
- Merck KGaA
- Start
- Jun 2024
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 25
01
Overview
A Phase 3 trial of cladribine in myasthenia gravis (MG), sponsored by Merck KGaA. Started Jun 2024; status: recruiting.
02
Drugs
cladribine
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06463587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06463587.